Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
The continuum of abnormal glucose tolerance (AGT) from insulin resistance (IR) and impaired glucose tolerance to diabetes, is found in 40 – 60% of patients with heart failure (HF), and all have a deleterious effect on patient outcomes. Dr. Wolfram Doehner (DE) emphasised the dual causal relationship between AGT and HF, and the complex metabolic pathways that lead to AGT in HF. For the patient who is diabetic, the relationship between hyperglycaemia and heart failure is a continuum stated Dr. A. Avagaro (IT). Dr. Avagaro further noted the challenges in glycaemic control for patients with HF, as some drugs may be contraindicated in ischaemia and as HF progresses. Dr. Clyde Yancey (US) stressed that development of diabetic cardiomyopathy is a risk for the 180 million people with diabetes worldwide, especially if they have retinopathy. High mobility group box-1 protein may be a missing link between diabetes and HF, and a potential novel therapeutic target, said Dr. Yancey. Given the deleterious effect of AGT on patients with HF, should we be routinely screening patients without known diabetes and if so how? Dr. Mamas (UK) advocated the use of the FINDRISK score to identify patients at highest risk of AGR, followed by an oral glucose tolerance test and HbA1c, as fasting glucose alone is likely to miss up to 80% of patients with AGT. All speakers identified the importance of AGT in patients with HF, and the need for better methods to prevent, detect and treat patients. Although new pharmacologic agents are needed, lifestyle changes, especially exercise, are important and effective treatment modalities.
Impaired glucose tolerance in heart failure